Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies

More drugs on the market, more targets in the pipeline

Publication Date	October 2006
Publisher	Datamonitor
Product Type	Report
Pages	430
ISBN Number	not applicable
Product Code	DAT04180

Buy this product or for assistance call +44 20 7060 7474

PDF £8,070.00$13234 | €8935

FAX Order above formats by FAX

Summary

Introduction

Cancer treatment continues to embrace the inclusion of molecular targeted therapies (MTT) into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.

Scope

Seven major pharmaceutical market sales forecasts from 2005 to 2015 for approved molecular targeted therapies and key pipeline candidates
Review of the current targeted therapies market, including profiles, product-specific assumptions and events over the forecasted period
Research and analysis of the targeted therapies pipeline with in-depth clinical and commercial assessment of Phase III candidates, plus expert opinion
Examination of product pipeline by phase, mode of action, indication, drug class and developer, plus two commercial impact case studies

Highlights

In 2005, the MTT market was worth $7.5 billion and the forecast sales of already marketed drugs in this class are expected to grow to $25.2 billion by 2015, at a CAGR of 12.9%. This growth will be driven mainly by Genentech/Roche's Rituxan, Herceptin and Avastin as well as Novartis' Gleevec, all of which have already reached blockbuster status.

274 different pipeline MTTs have been identified. The introduction of current late-phase candidates, including the pre-registered agents Tykerb (lapatinib; GlaxoSmithKline) and Zolinza (vorinostat; Merck), will further increase the market's total value by $3.8 billion, enabling the targeted therapies market to reach $29.1 billion in 2015.

The rise in cost of cancer treatment is unsustainable with growing pharmacoeconomic pressures challenging healthcare payers globally. To counter these hurdles, developers must become more effective at communicating the value of their products. To this end, a comprehensive understanding of the targeted therapies market and pipeline is critical.

Reasons to Purchase

Acquire a detailed appreciation and impartial perspective of the targeted cancer therapies market as a whole
Consider and react to the specific events influencing the future potential of marketed and pipeline targeted therapies
Gain an insight into the emerging clinical, developmental and commercial challenges and opportunities facing key developmental and marketed MTT drugs

Content

Chapter 1 Executive Summary
- Scope of analysis
- Datamonitor insight into the targeted therapies market
Chapter 2 Pipeline Overview
- Pipeline overview
- Pipeline by developmental phase and class of drug
- The cell cycle and apoptosis targeted agents make up the largest number of MTTs in the pipeline
- Segmentation of drugs by developmental phase reflects attrition rate of drug development in the oncology market
- Targeted therapy remains a promising anticancer drug development strategy
- Developmental agents by phase for each class
- Pipeline by indication
- MTTs are being investigated in 29 different cancers
- The 'big four' tumor types are the most popular indications for development
- Pipeline by mode of action
- Pipeline MTTs are being directed against a huge variety and combination of molecular targets
- The VEGF/VEGFR family remains the focus of development for MTTs
- Pipeline by company
- There are over 150 different companies developing targeted therapies
- Top three companies in terms of number of pipeline MTT products are Pfizer, Novartis and GlaxoSmithKline
- Pfizer
- Novartis
- GlaxoSmithKline
- Key metrics
- Datamonitor pipeline assessment summary
Chapter 3 Pipeline Dynamics
- A diverse range of disease subtypes
- Genetic basis of cancer evolution
- Tumorigenesis is the result of co-operative accumulated mutations
- Existing pharmacotherapy approaches provide limited treatment benefit
- Cytotoxic drugs lack specificity
- Hormonal or endocrine therapy provides incremental benefit in selected tumors
- Optimizing current treatment strategies is paramount
- The emergence of targeted treatment heralds a revolution in cancer pharmacotherapy
- Dynamic cancer market offers significant commercial opportunity
- Ongoing sales growth drives the market
- Intensive R&D produces a rich developmental pipeline
- Growing patient population and significant unmet needs propel innovation in the cancer market
- Cancer epidemiology - an expanding patient base
- Significant areas of unmet need persist
- Clinical and strategic threats to the commercialization of cancer drugs
- Progressively rising R&D costs threaten industry productivity
- High attrition rates can be mitigated by improved strategic decision-making
- Lengthening drug approval process - a consequence of increased regulatory demands
- Pharmacoeconomic pressures drive payers to implement restrictive pricing and reimbursement policies
- Therapeutic and generic competition reduces periods of market exclusivity
- Segmentation of market will require changes in clinical trial methodology
Chapter 4 Market Definition & Pipeline Classification
- Targeted therapies overview
- The development of molecular targeted therapies
- Current therapies are less cancer cell-specific
- The strategy is to target the specific survival factors of a tumor
- Key issue is the identification of targets unique to cancer cells
- Market definition
- L1X3 - Antineoplastic monoclonal antibodies
- L1X9 - All other antineoplastics
- Classification of pipeline products
- Angiogenesis inhibitors
- Angiogenesis as a normal biological process
- Angiogenesis is known to be abberant in tumor cell proliferation
- Angiogenesis inhibitors as viable antitumor agents can target a number of pathways
- At present, only one angiogenesis inhibitor exists in the market
- Single-target signal transduction inhibitors
- A plethora of potential targets exist along the signaling cascade
- Several signal transduction inhibitors have reached the market, bringing with them their own sets of issues for consideration
- Multi-targeted inhibitors
- Multi-targeted inhibitors have certain advantages over single targeted agents
- Approval of three multi-targeted inhibitors
- Cell cycle and apoptosis targeted inhibitors
- Only one cell cycle inhibitor has entered Phase III
- Cell death can be induced via a number of different pathways
- To date, only one apoptosis stimulator has reached the market
- Epigenetic modulators
- Despite relative immaturity of development in this class of drugs, the potential to enhance current therapies exists
- Immunomodulatory and immunoconjugated therapeutics
- Antibody-based technologies are an effective anticancer approach
- Pipeline comparator
- Current market situation
Chapter 5 Marketed Products Forecast Analysis
- Country-specific assumptions and effects
- Effect of Medicare Modernization Act in the US
- Biennial price cuts in Japan
- national Institute of Clinical Excellence in the UK
- Generic erosion assumptions
- Product assumptions and effects
- Angiogenesis inhibitors
- Genentech/Roche's Avastin (bevacizumab)
- Single-target signal transduction inhibitors
- ImClone/Bristol-Myers Squibb/Merck KGaA's Erbitux (cetuximab)
- Novartis's Gleevec/Glivec (imatinib)
- Genentech/Roche's Herceptin (trastuzumab)
- AstraZeneca's Iressa (gefitinib)
- OSI Pharmaceuticals/Genentech/Roche's Tarceva (erlotinib)
- Eisai's Targretin (bexarotene)
- Multi-targeted inhibitors
- Onyx Pharmaceuticals/Bayer AG's Nexavar (sorafenib)
- Bristol-Myers Squibb's Sprycel (dasatinib)
- Pfizer's Sutent (sunitinib)
- Cell cycle and apoptosis targeted agents
- Ortho Biotech/Millennium Pharmaceuticals' Velcade (bortezomib)
- Immunomodulatory and immunoconjugated therapeutics
- GlakoSmithKline's Bexxar (tositumomab)
- Schering AG/Berlex's Campath (MabCampath; alemtuzumab)
- Wyeth's Mylotarg (gemtuzumab)
- Biogen IDEC/Genentech/Roche's Rituxan/MabThera (rituximab)
- Biogen Idec/Schering AG's Zevalin (ibritumomab)
- Eisai's Ontak (Onzar; denileukin)
- Forecasts
Chapter 6 Pipeline Angiogenesis Inhibitors Analysis & Forecasts
- Pipeline overview
- AstraZeneca's AZD2171
- Drug Profile
- Clinical Trial Data
- AZD2171 as a monotherapeutic agent
- AZD2171 in combination with chemotherapy appears to be a promising approach
- AZD2171 has potential in NSCLC in combination with standard chemotherapy regimens and with Iressa
- Datamonitor Comments
- As a potentially more potent inhibitor of angiogenesis, and given its formulation, AZD2171's future may be very promising
- AstraZeneca's strength in the oncology market will be key in AZD2171's success
- GlaxoSmithKline's Pazopanib (GW 786034)
- Drug Profile
- Clinical Trial Data
- Pazopanib as a possible second-line monotherapy treatment for metastatic RCC
- Co-administration with Tykerb may alter the pharmacokinetics of pazopanib
- Other Indications
- Datamonitor Comments
- Initial approval in RCC will force pazopanib to compete against the already approved Sutent and Nexavar
- Tykerb may well enhance the success of pazopanib but at what price?
- Novartis/Schering AG's Vatalanib (PTK-787)
- Drug Profile
- Clinical Trial Data
- Anticipated regulatory filing for vatalanib in CRC is becoming increasingly unlikely following disappointing CONFIRM-1 and CONFIRM-2 interim results
- Recent update of vatalanib in Gleevec-resistant GIST patients
- Recent update of the Phase II GOAL Study in NSCLC
- Novartis/Schering AG adopt an aggressive approach, investigating vatalanib in a number of indications
- Datamonitor Comments
- Vatalanib unlikely to compete with Avastin in the metastatic CRC market
- Schering AG's and particularly Novartis's prior oncology experience will be invaluable to vatalanib
- Novartis and Schering AG are determined to exploit any commercial potential vatalanib may have
- Sanofi Aventis/Regeneron's VEGF-Trap
- Drug Profile
- Clinical Trial Data
- VEGF-Trap enters Phase III for ovarian cancer
- VEGF-Trap in Phase II for NSCLC and RCC
- Selecetd Phase I clinical studies in solid tumors
- VEGF-Trap demonstrates similar side effects to Avastin
- Datamonitor Comments
- Fierce competition with Avastin in the ovarian cancer market
- Presence in oncology field will aid commercialisation of VEGF-Trap
- Forecasts
- Datamonitor drug assessment summary
Chapter 7 Pipeline Single-Target Signal Transduction Inhibitors Analysis & Forecasts
- Pipeline overview
- Amgen's Vectibix (panitumumab; ABX-EGF)
- Drug Profile
- Overexpression of EGFR makes an ideal target for Vectibix development
- Clinical Trial Data
- Vectibix is approved for metastatic CRC and showing promise in a range of other treatment settings
- Addition of Vectibix does not enhance standard chemotherapy in NSCLC
- Vectibix fails as a single agent in RCC
- Main side effect is a potential indicator of Vectibix activity
- Datamonitor Comments
- Humanized nature of Vectibix will challenge its competitor EGFR inhibitors
- Vectibix versus Erbitux
- Third-line setting for metastatic CRC is a good place to start
- Amgen should focus on combination regimens while considering the intellectual property issues
- Potential development of a biomarker for Vectibix
- Amgen's presence will ensure success with profitability increasing by targeting earlier lines of therapy
- Schering-Plough's Sarasar (Lonafarnib)
- Drug Profile
- Clinical Trial Data
- Main focus of Sarasar development in MDS, where greatest antitumor activity is shown
- Farnesyl transferase inhibitors predominately in hematological disorders
- Lack of efficacy has led to termination of pivotal Phase III trial in NSCLC
- Lack of clinical data makes it difficult to judge Sarasar's potential in breast cancer
- Initiation of a Phase II trial in Ovarian Cancer
- Benefit shown in advanced head and neck cancer, although no further trials have been announced
- Currently no further trials planned for pancreatic cancer, urothelial carcinoma and colorectal cancer
- Mild toxicity in the majority of patients, although grade 3 events do occur
- Datamonitor Comments
- Sarasar's chances for approval will be delayed beyond 2007
- Sarasar racing against Johnson & Johnson's Zarnestra as the first farnesyl transferase inhibitor to reach the market
- Presence in oncology market will aid commercialization of Sarasar
- Abbott Laboratories' Xinlay (atrasentan)
- Drug Profile
- Xinlay's target receptor plays a key role in cancer cell proliferation
- Clinical Trial Data
- FDA do not approve Xinlay for prostate cancer
- Other trials
- Datamonitor Comments
- Despite its rejection by the FDA, Xinlay's future may still be promising
- Abbott's favorable position in the prostate cancer market will be invaluable
- Wyeth's Torisel (Temsirolimus; CCI-779)
- Drug Profile
- Temsirolimus inhibits a key pathway in tumor cell proliferation
- Clinical Trial Data
- Promising Phase III results in RCC reported at ASCO 2006
- Torisel showing promise in mantle cell lymphoma
- Torisel trial in breast cancer is discontinued
- Combination studies with Torisel initiated in malignant melanoma
- Combination studies with Torisel initiated in glioblastome multiforme
- Torisel as a monotherapy
- Mild toxicity means Torisel is well tolerated
- Datamonitor Comments
- Targeting poor prognosis patients may eventually accelerate Torisel's expansion within RCC
- Torisel will have to face Velcade in the MCL market
- Prior commercialization of Mylotarg and Neumega will provide Wyeth with valuable insight into the oncology market
- Janssen/Johnson & Johnson's Zarnestra (tipifarnib)
- Drug Profile
- Clinical Trial Data
- Following rejection of NDA, the FDA requires Phase III data for Zarnestra in AML before regulatory approval can be considered
- Zarnestra shows activity in MDS
- Zarnestra development in breast cancer remains in Phase II trials
- Following modest activity in brain cancer, further trials have been initiated
- Initiation of Phase II trials in large granular lymphocyte leukemia and malignant melanoma
- Negative Phase III trial results caused termination of development in solid tumors
- Phase I trial is ongoing for Zarnestra in combination with chemotherapy in advanced NSCLC
- Mild toxicity is particularly significant since Zarnestra's main indication is for elderly AML patients where quality of life is a major issue
- Datamonitor Comments
- Schering-Plough's Sarasar catching up with Zarnestra as the first farnesyl transferase inhibitor to reach the market
- Johnson & Johnson limiting Zarnestra's target population in the short term
- Johnson & Johnson's experience will be invaluable to Zarnestra
- YM Bioscience's TheraCIM (Theraloc; Nimotuzumab)
- Drug Profile
- Clinical Trial Data
- Phase III for pediatric pontine (brain stem) glioma
- Phase II pediatric trial demonstrated activity
- Positive efficacy and favorable toxicity data for Phase II trial results of TheraCIM
- Datamonitor Comments
- Phase III trial results required to verify the efficacy of this agent
- Forecasts
- Datamonitor drug assessment summary
Chapter 8 Pipeline Multi-Targeted Inhibitors Analysis & Forecasts
- Pipeline overview
- GlaxoSmithKline's Tykerb/Tycerb (Lapatinib)
- Drug Profile
- Tykerb is unique among the EGFR inhibitors, targeting two receptor tyrosine kinases
- Clinical Trial Data
- Tykerb set to penetrate the breast cancer market
- Tykerb did not meet the primary endpoint in mRCC Phase III study
- Tykerb monotherapy shows no activity in BTC but shows promise in HCC
- Tykerb appears to have little activity in SCCHN
- Other clinical trials
- Datamonitor Comments
- Tykerb's dual ErbB targeting mechanism will lead to a significant patient potential
- Tykerb and capecitabine combination looking to become the gold-standard for second-line metastatic beast cancer
- Tykerb's ability to threaten Herceptin still hangs in the balance
- GSK also looks to secure a future for Tykerb as part of combination regimens
- GSK's limited oncology portfolio will be bolstered by the arrival of Tykerb
- ChemGenex Pharmaceuticals' Ceflatonin (CGX-635, Myelostat)
- Drug Profile
- Clinical Trial Data
- Ceflatonin aims to restore Gleevec sensitivity in CML patients
- Datamonitor Comments
- Despite convincing clinical benefit, Ceflatonin will face strong competition from Bristol-Myers Squibb's Sprycel and Novartis's Tasigna
- Ipsen's Somatuline (Lanreotide)
- Drug Profile
- Clinical Trial Data
- Somatuline enters Phase III for entero-pancreatic endocrine tumors
- Somatuline in neuroendocrine tumors
- Datamonitor Comments
- Somatuline will benefit from its marketed status
- Somatuline may end up competing with Sutent in neuroendocrine tumors
- Novartis's Tasigna (Nilotinib, AMN-107)
- Drug Profile
- Clinical Trial Data
- Tasigna receives fast track and orphan drug status for Gleevec-resistant CML
- Promising Phase II interim data reported
- Only one BCR-ABL mutation is insensitive to Tasigna
- Tasigna shows promise for Gleevec-resistant metastatic GIST patients
- Datamonitor Comments
- Tasigna ready to challenge Bristol-Myers Squibb's already approved Sprycel
- Novartis looking to expand its leading role in the CML therapy market
- AstraZeneca's Zactima (Vandetanib; ZD6474)
- Drug Profile
- Clinical Trial Data
- Zactima granted Orphan Drug designation and Fast Track status for Thyroid cancer
- Following promising Phase II results, a Phase III trial of Zactima in combination with Taxotere has begun in NSCLC
- Zactima shown to be more effective than Gefitinib in NSCLC
- Initiation of Phase II trial in Glioma
- Datamonitor Comments
- Zactima set to enjoy a monopoly of thyroid cancer niche market
- Only two other agents share the multi-targeted characteristics of Zactima
- Zactima will need to overcome Tarceva in the NSCLC market
- AstraZeneca's strength in the oncology market will be key in Zactima's success
- Eli Lilly's Enzastaurin (LY317615)
- Drug Profile
- Clinical Trial Data
- Enzastaurin granted Orphan Drug status by the EMEA and FDA
- Enzastaurin in Phase III for Glioblastoma Multiforme
- Enzastaurin in Phase III for B-Cell Lymphoma
- Other clinical trials
- Datamonitor Comments
- Enzastaurin fulfills significant unmet needs in recurrent GBM setting
- Eli Lilly adopt a risky stragtegy for enzastaurin in BCL
- Eli Lilly
- Cephalon's Lestaurtinib (CEP-701)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
- Lestaurtinib may be the first in its class to reach the market
- Cephalon's recent acquisition of Trisenox will provide invaluable experience of the leukemia market
- Forecasts
- Datamonitor drug assessment summary
Chapter 9 Pipeline Cell Cycle And Apoptosis Targeted Agents Analysis & Forecasts
- Pipeline overview
- Genta's Genasense (Oblimersen)
- Drug Profile
- Despite termination of Genta's agreement with Sanofi-Aventis, Genasense remains in development for a multitude of indications
- Clinical Trial Data
- Benefits of Genasense in CLL may not be enough to offset the addition of significant toxicity
- Long-term survival results of Genasense in malignant melanoma are of significance
- Disappointing Phase III trial results in multiple myeloma means status of further development is unclear
- Early-phase benefits of Genasense in AML require confirmation in Phase III clinical trial
- Promise shown in combination with rituximab in NHL, but randomized trials have yet to be initiated
- Lack of clinical data in NSCLC makes it difficult to judge Genasense's potential
- Encouraging Phase II results in prostate cancer, though Phase III trials have yet to be initiated
- Ongoing Phase II trial in SCLC will determine if patient benefit counters additional toxicity
- Genasense did not enhance activity of standard interferon-alfa in RCC
- Other trials
- Datamonitor Comments
- Approval of Genasense is looking increasingly unlikely
- Termination of agreement with Sanofi-Aventis is a major setback for Genta
- Telik's Telcyta (TLK286)
- Drug Profile
- Telcyta: a small molecule prodrug with dual antitumor activity developed using Telcyta's TRAP technology
- Clinical Trial Data
- Telcyta has Fast Track status for both NSCLC and Ovarian cancer
- Telcyta in NSCLC
- Telcyta in ovarian cancer
- Telcyta shows some activity as a single agent in breast cancer, although final Phase II results have yet to be published
- Datamonitor Comments
- Telik was unfortunate to use Iressa as a comparator in Telcyta's ASSIST-2 trial
- Penetrating the second- and third-line ovarian cancer market
- Without a partner, Telik will struggle to commercialize Telcyta
- Celtic Pharma/Xenova's TransMID (XR-311)
- Drug Profile
- TransMID's target is highly relevant in glioma
- Clinical Trial Data
- Encouraging Phase II results, active clinical trial program and Fast Track designation will drive development of TransMID
- Datamonitor Comments
- Cumbersome infusion schedule and administration may detract from TransMID's broad clinical benefit
- Although Xenova has secured several marketing partnerships, a glaring omission is one in the lucrative US market
- Sanofi-Aventis's Alvocidib (Flavopiridol)
- Drug Profile
- Clinical Trial Data
- Continuous infusion dosing schedules fail to demonstrate clinical activity
- Modified dosing regimen drives further development in CLL
- Alvocidib proves ineffective in hepatocellular carcinoma
- Initiation of a Phase II trial involving alvocidib in pancreatic cancer
- Datamonitor Comments
- Alvocidib's checkered history leaves KOLs cynical about its future clinical potential
- Alvocidib may show more promise as part of a combination regimen
- Presence in oncology field will aid commercialization of alvocidib
- Novogen's Phenoxodiol
- Drug Profile
- Clinical Trial Data
- Phenoxodiol's Fast Track status in Ovarian Cancer
- The OVATURE trials
- Initiation of a Phase I/II trial for Phenoxodiol plus Taxotere in ovarian cancer
- Phenoxodiol in Phase I for a variety of solid tumors
- Datamonitor Comments
- Toxicity will be the key factor for phenoxodiol's success
- Sanofi-Aventis as a marketing partner?
- Forecasts
- Datamonitor drug assessment summary
Chapter 10 Pipeline Epigenetic Modulators Analysis & Forecasts
- Pipeline overview
- Merck's Zolinza (Vorinostat, SAHA)
- Drug Profile
- Clinical Trial Data
- Zolinza granted Priority Review for CTCL following promising Phase IIb results
- FDA granted Orphan Drug designation for multiple myeloma
- Zolinza in Phase III trial for malignant pleural mesothelioma
- Other clinical trials
- Datamonitor Comments
- Zolinza will serve to increase Merck's oncology portfolio
- Merck conscious to not limit the use of Zolinza to just CTCL and myeloma
- Zolinza may face competition from Gloucester Pharmaceuticals' romidepsin
- Gloucester Pharmaceuticals' Romidepsin (FK-228, depsipeptide)
- Drug Profile
- Broad range of HDAC inhibition should theoretically provide increased efficacy
- Clinical Trial Data
- Romidepsin has fast track status and orphan drug status for CTCL
- Encouraging results in CTCL require replication in a Phase III clinical trial
- Romidepsin also showing promise in PTCL
- Romidepsin in Phase II for HRPC despite lack of preclinical evidence for this indication
- Datamonitor Comments
- Romidepsin may have difficulty competing with Merck's Zolinza in the CTCL market
- Further evaluation is needed to establish the clinical activity of combination therapy using HDAC inhibitors with cytotoxic drugs
- Commercial success of romidepsin will rely on Gloucester Pharmaceuticals collaborating with large pharma
- Forecasts
- Datamonitor drug assessment summary
Chapter 11 Pipeline Immunomodulatory And Immunoconjugated Therapeutics Analysis & Forecasts
- Pipeline overview
- Wilex's Rencarex (WX-G250)
- Drug Profile
Mn/Ca Ix Antigen - A Highly Specific Tumor Target
- Mode of Action of Rencarex - ADCC
- Clinical Trial Data
- Rencarex in Phase III for non-metastatic RCC (the ARISER trial)
- Completed Phase I & II trials for metastatic RCC
- Datamonitor Comments
- Rencarex may face a number of hurdles
- Genmab's Ofatumumab (HuMax-CD20)
- Drug Profile
- Clinical Trial Data
- Genmab hoping ofatumumab will demonstrate a preferred efficacy profile over Rituxan in the clinic
- Ofatumumab receives fast track status for CLL and enters a Phase III trial
- Genmab initiate a pivotal trial in NHL
- Datamonitor Comments
- Genmab should look to compare ofatumumab with Rituxan in a Phase III trial
- Commercial success of ofatumumab will rely on Genmab collaborating with large pharma
- Forecasts
- Datamonitor drug assessment summary
Chapter 12 Commercial Impact & Lifecycle Management: Case Studies
- Introduction
- Case study one
- Clinical, developmental and commercial challenges to combining molecular targeted therapies
- How to optimally utilize molecular targeted therapies in the context of combinatorial regimens
- Intellectual property implications associated with combining targeted therapies
- Lessons to be learnt from already marketed targeted therapies
- Differences and similarities between monoclonal antibodes and small molecules
- Effectively demonstrating the clinical and pharmacoeconomic value of combinatorial MTT strategies is critical
- Case study two
- Comparing marketed and pipeline MTTs: The evolving trends
- Segmentation of MTTs by structural class
- Segmentation of MTTs by indication
- Approval paths experienced by the marketed MTTs
- Developing a targeted therapy for a niche tumor over one of the 'big four' tumor types - Which strategy should Pharma pursue?
Appendix A - Market Data & Major Brand Key Facts
- L1X3 (antineoplastic monoclonal antibodies) class market data
- L1X9 (all other neoplastics) class market data
- Sales data and forecasts
- PowerPoint Executive Presentation
Appendix B - Sales Forecasts
- US Forecasts
- Japan Forecasts
- France Forecasts
- Germany Forecasts
- Italy Forecasts
- Spain Forecasts
- UK Forecasts
- Five Major European Markets (EU5) Forecasts
- Seven Major Markets Forecasts
Appendix C
List of Tables
List of Figures
- Methodology
- Datamonitor forecast methodology
- Forecasts for marketed drugs
- Forecasts for pipeline drugs
- Datamonitor drug assessment methodology
- Abbreviations
- Contributing experts
- Bibliography
- About Datamonitor
- About Datamonitor Healthcare
- About the Oncology analysis team
- Disclaimer